Skip to main content
Premium Trial:

Request an Annual Quote

Benitec Hits Dosing Delay in HCV Trial


NEW YORK (GenomeWeb) – Benitec Biopharma last week disclosed delays in its efforts to dose patients in a Phase I/IIa trial of its expressed RNAi-based hepatitis C treatment TT-034 and said that it is taking steps to speed subject enrollment.

TT-034 is designed to express shRNAs targeting three portions of the HCV genome and was administered to the first patient in the planned 14-patient trial in June. However, Benitec said this week that dosing additional patients in that study is taking longer than anticipated due to the failure of two patients to meet trial inclusion criteria.

During a 28-day monitoring process, the company said, these patients experienced fluctuations in viral load and/or liver enzymes that were beyond the acceptable limits of the Phase I/IIa trial. Currently, additional patients are going through the monitoring process, and the first to satisfy the study criteria will be dosed.

At the same time, Benitec said it is working to accelerate patient enrollment by adding clinical trial sites to the TT-034 program, reviewing the study's enrollment process to "identify areas of enhancement," and appointing a clinical trial specialist to "actively manage" the study in collaboration with the contract research organization managing it.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.